Lilly Q2 revenue $8.31B (+28%), EPS $1.95 (+86%), raises FY guidance

ELI LILLY & Co

2023-Q2 EPS reported $3.44 revenue$15,272,100,000

Q2 revenue $8,312M, up 28% YoY; reported EPS $1.95 (+86%); non-GAAP EPS $2.11 (+69%, includes $0.43 from Baqsimi rights sale).
FY 2023 reported EPS guidance raised to $9.20-$9.40; non-GAAP EPS raised to $9.70-$9.90, up $1.02 and $1.05 respectively.
Mounjaro led New Products with $1.00B revenue; Growth Products up 16% to $4.93B, led by Verzenio, Jardiance, Taltz.
Pipeline progress: donanemab submitted to FDA/EMA for Alzheimer's; tirzepatide submitted for chronic weight management; mirikizumab approved in EU.
Announced agreements to acquire DICE Therapeutics, Sigilon Therapeutics, and Versanis Bio to expand autoimmune and cardiometabolic pipeline.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ELI LILLY & Co reported the second quarter of 2023 results: revenue $8,312.1, net income $1,763.2, EPS $1.95. Guidance raised.

Period: the second quarter of 2023
Revenue: $8,312.1
Net income: $1,763.2
EPS: $1.95
Guidance: raised
Result: reported results

Exact text from the filing

on important public announcements, visit the news section of Lilly's website. 2 Financial Results $ in millions, except per share data Second Quarter 2023 2022 % Change Revenue $8,312.1 $6,488.0 28% Net Income – Reported 1,763.2 952.5 85% EPS – Reported 1.95 1.05 86% Net Income – Non-GAAP 1,904.4 1,131.3 68% EPS – Non-GAAP 2.11 1.25 69% A discussion of the

View on SEC.gov

Browse all earnings releases →

ELI LILLY & Co filing history →

Source: SEC EDGAR

accession 0000059478-23-000219

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.